CD274 and non-small cell lung carcinoma: ICIs, including anti-programmed death 1 (anti-PD-1) and anti-programmed death ligand 1 (anti-PD-L1) inhibitors with platinum-based chemotherapy (chemo-ICI), have become the standard first-line treatments for metastatic and locally advanced NSCLC, as demonstrated in several randomized phase III trials [1,2,3].